The asset return removes a partnership constraint but does not solve the near-term cash runway issue. Watch for partnership announcements or financing events in the coming weeks, as the company's cash position was sufficient only through mid-2026 per the prior 20-F.
Price Chart
Executive Summary
Addex Therapeutics regained full global rights to its GABAB PAM portfolio from Indivior after Indivior rationalized R&D and announced a planned merger with Supernus Pharmaceuticals. The returned asset includes a development candidate for substance use disorders that completed IND-enabling studies, plus a proprietary chronic cough program. This non-cash event eliminates a partnership constraint but provides no new funding, leaving the company's precarious cash position (CHF 1.6M as of FY2025, sufficient only through mid-2026 per the prior 20-F) unchanged.
Key Facts
- Addex regained full global rights to all GABAB PAM assets from Indivior following Indivior's R&D rationalization and planned merger with Supernus Pharmaceuticals.
- The returned development candidate for substance use disorders has completed IND-enabling studies; the proprietary chronic cough program is ready to start IND-enabling studies.
- No financial terms of the asset return were disclosed; no upfront or milestone payments were mentioned.
- The prior 20-F (May 2026) reported cash of CHF 1.6M, sufficient only through mid-2026, with a going concern emphasis.
- CEO Tim Dyer stated the company will evaluate strategic options including new partnerships or advancing programs before partnering.
- Recent SC 13D/A filings (Aug 27 and Sep 4, 2026) by CEO Tim Dyer indicate activist-level insider stake activity.
Financial Impact
No financial consideration disclosed; the asset return is non-cash and does not address Addex's cash runway, which was reported at CHF 1.6M as of FY2025 year-end.
Risk Factors
- Cash runway remains critically short (CHF 1.6M as of FY2025 year-end) with no new funding announced.
- No guaranteed partnership or licensing deal for the returned GABAB PAM assets; monetization timeline uncertain.
- Going concern risk persists from the prior 20-F auditor emphasis.
- Activist insider stake (SC 13D/A filings by CEO Tim Dyer) adds governance uncertainty.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006225 |
| Document: f6k_092526.htm | 0001171843-26-006225 |
| Document: 0001171843-26-006225-index-headers.html | 0001171843-26-006225 |
| Document: 0001171843-26-006225-index.html | 0001171843-26-006225 |
| Document: 0001171843-26-006225.txt | 0001171843-26-006225 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.18 | awaiting T+60 | — | $2.99 (−5.97%) |
Oct 2, 2026 25d ago | 6-K | $3.07 | awaiting T+60 | — | $2.99 (−2.61%) |
Sep 28, 2026 29d ago | 6-K | $2.81 | awaiting T+60 | — | $2.99 (−6.41%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.99 (−18.08%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.99 (+29.31%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.99 (−49.24%) |
Jun 30, 2026 17w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.99 (+47.54%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.99 (+49.66%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.99 (+56.22%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.99 (−51.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers